metsera glp-1 MET-097i results from two trials at ObesityWeek Metsera: An Emerging Contender In

Yeah, so I had a bit of a search around for this and theres not this really not much detailed about what the long-term effects of the use of GLP-1 receptor agonists is for the lay population or even for diabetics

In contrast, long-acting GLP-1RAs, including liraglutide, dulaglutide, semaglutide, and albiglutide, increase insulin secretion and decrease glucagon secretion, thus lowering fasting and postprandial blood glucose levels (Thomas et al., 2023)

The article names baseline kidney function, concurrent medications that affect glutathione metabolism such as acetaminophen or chemotherapy agents, and existing gastrointestinal disorders that altered gastric transit could worsen

Some patients taking GLP-1 experience mild side effects

It is unknown whether the drugs pharmacokinetic profile would allow for a once daily administration

There are numerous studies that describe the various processes involved in APAP-induced liver injury using mathematical models